First-line bevacizumab-containing therapy for HER2-negative locally advanced/metastatic breast cancer: real-world experience from >2000 patients treated in the multicentre AVANTI study
Aim - The multicentre non-interventional AVANTI study assessed safety, effectiveness and patient-reported outcomes with approved first-line bevacizumab-containing regimens for HER2-negative locally recurrent/metastatic breast cancer (LR/MBC) in German routine oncology practice. - Methods - Eligible...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
December 2021
|
| In: |
The breast
Year: 2021, Volume: 60, Pages: 70-77 |
| ISSN: | 1532-3080 |
| DOI: | 10.1016/j.breast.2021.08.014 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.breast.2021.08.014 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0960977621004446 
|
| Author Notes: | Volkmar Müller, Markus Ruhnke, Oliver Hoffmann, Andrea Grafe, Oliver Tomé, Werner Fett, Harald-Robert Bruch, Ann-Katrin Sommer-Joos, Andreas Schneeweiss |
| Summary: | Aim - The multicentre non-interventional AVANTI study assessed safety, effectiveness and patient-reported outcomes with approved first-line bevacizumab-containing regimens for HER2-negative locally recurrent/metastatic breast cancer (LR/MBC) in German routine oncology practice. - Methods - Eligible patients had HER2-negative LR/MBC, no bevacizumab contraindications and no prior chemotherapy for LR/MBC. Chemotherapy schedule, diagnostics and follow-up were at physicians’ discretion. Data were collected for 1 year after starting bevacizumab, then every 6 months for 1.5 years (maximum follow-up: 2.5 years). Patients and physicians rated treatment satisfaction. Subgroup analyses were prespecified in clinically relevant populations, including triple-negative breast cancer (TNBC). - Results - Between November 1, 2009 and April 30, 2016, 2065 eligible patients at 346 centres received bevacizumab with paclitaxel or capecitabine. Patients receiving bevacizumab-capecitabine were less likely to have de novo disease and more likely to have TNBC, age ≥60 years and prior anthracycline/taxane and/or endocrine therapy. Median PFS was 12.6 (95% CI 11.9-13.2) months (12.8 with bevacizumab-paclitaxel, 10.5 with bevacizumab-capecitabine); median OS was 23.9 (95% CI 22.2-25.1) months. Outcomes were worse in patients with TNBC, prior anthracycline/taxane or prior endocrine therapy. Grade ≥3 adverse events occurred in 27% of patients. Treatment was discontinued for adverse events in 15%. Treatment satisfaction was rated as good or better by 304/394 responding patients (77%) at week 54 and in 1393/2065 patients (67%) by physicians overall. - Conclusions - In routine clinical practice, effectiveness and safety of first-line bevacizumab-containing therapy for LR/MBC were consistent with experience from phase III trials. Patient and physician treatment satisfaction showed high concordance. |
|---|---|
| Item Description: | Online veröffenticht am 27. August 2021, Artikelversion vom 3. September 2021 Gesehen am 06.12.2022 |
| Physical Description: | Online Resource |
| ISSN: | 1532-3080 |
| DOI: | 10.1016/j.breast.2021.08.014 |